22nd Century Hires Former Reynolds American Vice President
November 02 2017 - 9:50AM
Business Wire
James E. Swauger, Ph.D., will serve as 22nd
Century’s Senior VP of Science and Regulatory Affairs
22nd Century Group, Inc. (NYSE American: XXII), a plant
biotechnology company focused on tobacco harm reduction and
cannabis/hemp research, announced today the hiring of James E.
Swauger, Ph.D., as the Company’s Senior Vice President of Science
and Regulatory Affairs. Dr. Swauger was previously the leader of
the scientific and regulatory functions at Reynolds American Inc.
(“Reynolds”).
Dr. Swauger was employed for 23 years, from 1993 through 2016,
in various positions of significant scientific and regulatory
responsibility with Reynolds. From 2008 through 2016, while serving
as the Vice President of Regulatory Oversight, Dr. Swauger managed
the creation, submission and oversight of numerous scientific
applications and regulatory filings with the U.S. Food and Drug
Administration (“FDA”) and other federal, state, and local
regulatory agencies. Dr. Swauger received his Doctorate Degree in
Biochemical Toxicology from The Johns Hopkins University in 1990
and his Bachelor of Science Degree in Toxicology (Magna cum laude)
from Northeastern University in 1985.
Dr. Swauger’s primary responsibility at 22nd Century will be to
lead and oversee the scientific and regulatory activities of the
Company. He will spearhead the re-submission to the FDA of the
Company’s Modified Risk Tobacco Product (“MRTP”) application for
BRAND A Very Low Nicotine Content cigarettes, and will work in
support of the FDA’s plan to mandate the reduction of the nicotine
content of cigarettes to minimally or non-addictive levels. As
previously reported, on July 28, 2017, the FDA announced its plan
to mandate that all cigarettes sold in the United States contain
Very Low Nicotine tobacco. With 95% less nicotine than tobacco used
in conventional cigarettes, 22nd Century’s Very Low Nicotine
tobacco effectively demonstrates that the FDA’s nicotine targets
are both technically achievable and realistic; the Company’s
proprietary tobacco has been used in more than $100 million in
independent clinical studies funded by the FDA and other federal
government agencies.
“I am thrilled with the opportunity to join the 22nd Century
team and I look forward to working with a company that is dedicated
to reducing the harm caused by smoking,” explained Dr. Swauger. “It
is clear that 22nd Century’s proprietary Very Low Nicotine
technology is a leading driver in the tobacco harm reduction
movement. With the potential to prevent millions of premature
deaths and to save billions of dollars in healthcare costs, 22nd
Century’s technology is a game-changer.”
“Dr. Swauger’s past successes – in both the tobacco and
pharmaceutical businesses of a major tobacco company – are very
impressive,” explained Henry Sicignano, III, President and CEO of
22nd Century Group. “I am confident that Dr. Swauger’s extensive
regulatory and scientific leadership will prove invaluable to 22nd
Century as we aggressively push forward our MRTP application for
the world’s lowest nicotine tobacco cigarettes.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on genetic
engineering and plant breeding which allows the increase or
decrease of the level of nicotine in tobacco plants and the level
of cannabinoids in cannabis plants. The Company’s primary mission
in tobacco is to reduce the harm caused by smoking. The Company’s
primary mission in cannabis is to develop proprietary hemp/cannabis
strains for important new medicines and agricultural crops. Visit
www.xxiicentury.com and www.botanicalgenetics.com for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2016, filed on March 8, 2017,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171102005363/en/
22nd Century GroupJames Vail, 716-270-1523Director of
Communicationsjvail@xxiicentury.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024